Abstract
Percutaneous guided radiofrequency ablation (RFA) has become a valued tool in the management of patients with primary hepatic and secondary hepatic metastatic disease. A recent FDA approved endoscopic ultrasound (EUS) guided RFA probe now offers promise to help manage such patients. However, there are no data to determine the ideal power setting and duration of ablation needed to effectively treat hepatic masses. The aim of the study was to evaluate the macroscopic zone of hepatic injury for EUS RFA using a variety of settings within a fresh porcine hepatic specimen.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
